CytomX (CTMX) Q1 2026 Earnings Call Summary

CytomX reported Phase I data for Varseta-M in metastatic colorectal cancer, showing an overall response rate of 20-32% and a median progression-free survival of seven months. The company plans to begin registrational trials by mid-2027 after dose selection and FDA discussions.

By Motley Fool Transcribing · Motley Fool · May 8, 2026, 17:44 UTC

CytomX (CTMX) Q1 2026 Earnings Call Summary

Tickers: $CTMX

Topics: colorectal cancer CX-801 Phase I data Varseta-M

Read the full article at Motley Fool

More World news

CEZ Reports 9M Revenue Growth and 24% Increase in Net Income Seeking Alpha · November 12, 2026, 15:05 UTC
BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC
OpenAI Secures $15 Billion in New Funding at $1.25 Trillion Valuation Seeking Alpha · November 12, 2026, 15:13 UTC
Digi International Shares Fall 18% Following Fiscal Q4 Earnings Release Seeking Alpha · November 12, 2026, 15:13 UTC
Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events PR Newswire · November 12, 2026, 15:15 UTC
Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC
Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth Motley Fool · November 12, 2026, 15:09 UTC
Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks PR Newswire · November 12, 2026, 15:10 UTC